Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Uproleselan update: moving forward for R/R AML

Daniel DeAngelo • 8 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Uproleselan

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data on uproleselan (GMI-1271), a novel E-selectin antagonist, in acute myeloid leukemia (AML). This includes the upcoming phase 3 registration trial in the relapsed/refractory setting (NCT03616470) and work showing that uproleselan can overcome the chemotherapy resistance that high E-selectin ligand expression contributes to. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Daniel DeAngelo

Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
1:14
The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
Daniel DeAngelo • 6 Dec 2024
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL
0:42
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL
Daniel DeAngelo • 6 Dec 2024
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
0:53
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
Daniel DeAngelo • 6 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals